Opening: Real consultation scenario
▎Real consultation scenario
A 34-year-old woman, AMH 1.3 ng/mL, completed her first IVF at a reproductive center in Bishkek, Kyrgyzstan. After ovarian stimulation, 6 eggs were retrieved, 4 of which were mature, resulting in 2 day-3 embryos. One embryo was transferred but did not implant, and the other stopped developing in the laboratory. She sent a message asking: "Doctor, can I try again? How long do I need to wait? What are my chances of success if I try again?"
This is a very typical question in reproductive clinics. The anxiety and confusion after failure are real, and the answer is not simply a "yes" or "no."
I. Can IVF be done again after failure in Kyrgyzstan?
Yes, you can try again, but only if specific medical conditions are met. Whether you are suitable for the next cycle depends on the following four key judgments:
- Physical condition permits: No uncontrolled systemic diseases (such as hypertension, thyroid dysfunction, active autoimmune diseases), ovarian function has not declined to the point where effective eggs cannot be obtained, and the uterine shape and endometrial conditions have the potential for pregnancy.
- The cause of failure has been analyzed or there is a clear direction for adjustment: It is not recommended to directly repeat the same protocol without reviewing the cycle data and investigating common failure factors.
- There are still usable embryos or follicular reserve: If there are frozen embryos (especially euploid embryos), you can directly enter a frozen embryo transfer cycle; if there are no frozen embryos, you need to restart ovarian stimulation, and the possibility of ovarian response must be evaluated.
- The patient herself has the willingness to continue trying and fully understands the risk of another failure.
Conditions where an immediate second attempt is not suitable:
- Presence of untreated uterine pathology (e.g., large endometrial polyps, intrauterine adhesions, submucosal fibroids);
- Use of teratogenic drugs or pelvic radiotherapy within the last 3 months;
- Ovarian function is nearly depleted (e.g., AMH < 0.3 ng/mL and antral follicle count < 2), with a very poor response to ovarian stimulation drugs;
- Presence of uncontrolled systemic diseases (e.g., active thyroiditis, untreated hyperprolactinemia).
II. Why does failure occur? — Classification of common causes
The causes of IVF failure are multifactorial. From a reproductive medicine perspective, the influencing factors can be divided into the following four levels:
| Category of Cause | Specific Factors | Estimated Proportion |
|---|---|---|
| Embryo Factors | Chromosomal aneuploidy, embryo developmental arrest, severe fragmentation, multinucleation | Approximately 50–60% |
| Uterine Factors | Poor endometrial receptivity, intrauterine adhesions, endometrial polyps, submucosal fibroids, chronic endometritis | Approximately 20–30% |
| Maternal Factors | Thyroid dysfunction, positive autoimmune antibodies, coagulation abnormalities, vitamin D deficiency, metabolic syndrome | Approximately 10–15% |
| Technical Factors | Mismatch between stimulation protocol and ovarian response, timing of trigger, laboratory culture conditions, embryo transfer technique | Approximately 5–10% |
Embryo chromosomal abnormalities are the most common cause of single transfer failure. After the age of 35, the rate of egg chromosomal aneuploidy increases significantly, reaching approximately 40–50% at age 38 and over 70% after age 42.
III. How does a doctor evaluate "whether you can try again"?
From the perspective of reproductive medicine decision-making, a doctor will make a judgment based on the following logic:
1. Embryo Level
- Was the transferred embryo tested with PGT-A? If not, what is the likelihood of chromosomal abnormalities?
- If PGT-A was performed, was it a euploid embryo? If a euploid embryo still fails, the focus shifts to uterine and maternal factors.
- What is the developmental potential and grade of any remaining embryos? Are they worth using?
2. Uterine Level
- Is the uterine cavity shape normal? Are there any space-occupying lesions or adhesions?
- Are endometrial thickness, pattern, and blood flow signals adequate?
- Is there chronic endometritis (CD138 positive)? Is an ERA test needed to determine the window of implantation?
3. Maternal Level
- Are thyroid function (TSH, FT4) and thyroid autoantibodies (TPO-Ab, Tg-Ab) normal?
- Are antiphospholipid antibodies, antinuclear antibodies, and coagulation function (D-dimer, Protein S/C) abnormal?
- Are vitamin D, blood glucose, and insulin resistance within the ideal range?
4. Protocol Level
- Does the stimulation protocol (long protocol, antagonist protocol, mild stimulation, etc.) match the patient's ovarian response characteristics?
- Does the timing of the trigger and the fertilization method (IVF/ICSI) need adjustment?
- Is there room for optimization in the laboratory culture conditions (especially the blastocyst culture rate)?
▎Doctor's Key Point Causal analysis after failure is more important than blindly starting the next cycle. Repeating attempts without a clear cause will not naturally improve the success rate.
IV. Five most easily overlooked details
In the evaluation after IVF failure in Kyrgyzstan, the following details are often overlooked but are frequently the key:
- Embryo Chromosomal Euploidy: Embryos with high morphological scores can still be chromosomally aneuploid. For women aged ≥35 or those with recurrent implantation failure, PGT-A screening can significantly reduce failures due to chromosomal abnormalities.
- Chronic Endometritis: Often asymptomatic, it can be diagnosed through hysteroscopic endometrial biopsy + CD138 immunohistochemistry. After antibiotic treatment, the implantation rate in subsequent transfers can increase by 20–30%.
- Endometrial Receptivity (ERA Test): Approximately 20–30% of women have a displaced window of implantation (1–2 days earlier or later). The ERA test can personalize the optimal timing for embryo transfer.
- Male Sperm DNA Fragmentation Index (DFI): A high fragmentation rate (>30%) can affect embryo developmental potential and implantation capacity, even if routine semen parameters are normal. DFI can be detected by sperm chromatin dispersion test or flow cytometry.
- Positive Thyroid Autoantibodies: Women positive for TPO-Ab or Tg-Ab have a significantly higher risk of implantation failure and early miscarriage, even if TSH is within the normal range. It is recommended to control TSH to < 2.5 mIU/L during preconception.
V. Four most common pitfalls
| Common Misconception | Why It's a Pitfall | Correct Approach |
|---|---|---|
| Starting the next cycle without investigating the cause | The probability of failure with the same protocol is high, especially when embryo factors are not ruled out. | Complete a causal analysis before deciding on a new protocol. |
| Too short an interval (< 1 month) | The ovaries and endometrium need time to recover, and the hormonal environment is not stable. | Wait at least 1–2 menstrual cycles. |
| Blindly changing hospitals or doctors without providing complete medical records | The new doctor cannot understand previous medication responses and laboratory details, making accurate judgment difficult. | Organize all medical records (stimulation protocol, embryo records, transfer records) before seeking a second opinion. |
| Over-reliance on "lifestyle adjustments" while neglecting medical examinations | Lifestyle improvements are supportive measures and cannot replace cause investigation, potentially delaying the optimal window. | Prioritize medical examinations, and make lifestyle adjustments concurrently. |
VI. Practical process for a second attempt
From failure to the next cycle, it is recommended to follow these steps:
- Failure Cause Analysis (within 1–2 weeks after failure): Conduct a thorough review of the cycle data with your primary doctor, including stimulation medication, follicular development, embryo grading, and transfer records. Supplement with hysteroscopy, ERA, immune markers, etc., if necessary.
- Recovery Period (1–3 months): Discontinue all exogenous hormones (e.g., luteal phase support drugs) and wait for natural menstruation to resume. Supplement with folic acid (0.4–0.8 mg/day), vitamin D (adjusted based on serum levels), maintain a regular routine, and engage in moderate exercise.
- Develop a New Protocol (1–2 weeks after recovery): Based on the causal analysis, work with your doctor to determine adjustments to the stimulation protocol (or frozen embryo transfer protocol).
- Execute the New Cycle: Proceed with ovarian stimulation or endometrial preparation according to the new protocol. Confirm pregnancy via blood hCG 12–14 days after transfer.
Materials to prepare:
- All previous medical records (stimulation records, embryo culture records, transfer records, blood test results)
- Identification documents and marriage certificate for both partners (some centers in Kyrgyzstan require originals and notarized translations)
- Basic examinations within the last 3 months (complete blood count, coagulation, thyroid function, infectious disease screening)
- If PGT-A was performed, prepare the embryo biopsy report and genetic counseling records
VII. Timeline: How long from failure to the next transfer?
| Stage | Recommended Time | Notes |
|---|---|---|
| Failure Cause Analysis | 1–2 weeks after failure | Complete hysteroscopy, ERA, immune tests, etc. (some tests require specific menstrual cycle phases) |
| Recovery Period | 1–3 months | Stop hormones, allow 2–3 natural menstrual cycles |
| New Protocol Development | 1–2 weeks after recovery | In-person consultation with doctor to finalize stimulation or transfer protocol |
| Stimulation Cycle (if no frozen embryos) | Approximately 2–3 weeks | Medication starts from day 2–3 of menstruation until egg retrieval |
| Frozen Embryo Transfer Cycle (if frozen embryos available) | Approximately 2–4 weeks | Artificial or natural cycle for endometrial preparation |
Overall, from failure to the next transfer, it typically takes 3–6 months. For older women or those with diminished ovarian reserve, the recovery period can be shortened after completing necessary tests, but should not be less than 1 month.
VIII. Scenario analysis for different situations
Scenario 1 · 35 years old, AMH 1.2 ng/mL, 5 eggs retrieved, 1 transferred without implantation
Key analysis: Probability of embryo chromosomal abnormality is approximately 40–50%. PGT-A screening is recommended for the next cycle, along with an assessment of endometrial receptivity.
✅ A second attempt is feasible. Adjustment direction: Optimize the stimulation protocol to increase the number of eggs retrieved, perform PGT-A + ERA testing.
Scenario 2 · 42 years old, AMH 0.4 ng/mL, 2 eggs retrieved, no embryos available for transfer
Key analysis: Ovarian reserve is severely diminished, with very few eggs retrieved and limited embryo developmental potential. It is necessary to assess whether there are still follicles that respond to stimulation drugs.
⚠️ A second attempt requires caution. If ovarian function declines further, it may not be possible to retrieve eggs. Consider a mild stimulation protocol or egg donation.
Scenario 3 · 28 years old, Polycystic Ovary Syndrome, 2 day-3 embryos transferred, neither implanted
Key analysis: Embryo factors are relatively less likely. Focus on investigating endometritis, endometrial receptivity, and insulin resistance.
✅ A second attempt is feasible. Adjustment direction: Hysteroscopy + CD138 biopsy + ERA, control weight and insulin levels.
Scenario 4 · 39 years old, ICSI performed at a center in Kyrgyzstan, 1 blastocyst obtained, PGT-A showed euploid, but no implantation after transfer
Key analysis: Failure of a euploid embryo transfer strongly suggests uterine or maternal factors. Hysteroscopy, ERA, immune, and coagulation panels are required.
✅ A second attempt is feasible, but investigation and intervention for uterine and maternal factors must be completed first.